RCS - Celadon Pharma. PLC - West Midlands Mayor Visits Celadon’s Facility

Celadon PharmaceuticalsAnnouncement

25/05/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230525:nRSY6367Aa&default-theme=true

RNS Number : 6367A  Celadon Pharmaceuticals PLC  25 May 2023

Celadon Pharmaceuticals Plc

("Celadon" or the "Company")

West Midlands Mayor Visits Celadon's Cultivation and Manufacturing Facility

 

25 May 2023 - Celadon Pharmaceuticals Plc (AIM: CEL), a UK-based
pharmaceutical company focused on the research, cultivation, manufacturing and
sale of breakthrough cannabis-based medicines, was delighted to welcome Andy
Street, the Mayor of the West Midlands, to its cultivation and manufacturing
facility yesterday.

During his tour around Celadon's 100,000 sq ft facility, the Mayor was shown
the Company's cutting-edge indoor hydroponic cultivation area, its R&D
laboratory and its planned future expansion areas. He also outlined his
support for plans to make the West Midlands region a leading hub for the
manufacturing and R&D of cannabis-based medicines. At full capacity,
Celadon's facility is expected to produce medicines for around 50,000 UK
patients, bringing hundreds of high-skilled jobs to the West Midlands region,
in areas such as pharmaceutical R&D and agronomy.

Among those present to meet the Mayor were members of Celadon's senior
management team, including James Short (Chief Executive Officer); Arthur
Wakeley (Managing Director); and Iqbal Gill (Chief Scientific Officer). Future
expansion plans were discussed, with Celadon emphasising its desire to expand
in the West Midlands region and create the UK's centre of excellence for
cannabis-based medicines.

Celadon is part of the West Midlands' £6.5bn full-service healthcare and life
sciences economy. The region's diverse population of 4.7 million potential
trial participants, combined with excellent connectivity and valuable medtech
assets (including eight local hospitals and 35 regional centres of clinical
research excellence), make the region an ideal location for Celadon's
operations. In addition, the new powers and £1.5bn of funding recently
secured as part of the Deeper Devolution Deal, agreed between the West
Midlands Combined Authority and the UK government, will help the region to
realise its potential as home to the future of cutting-edge life science
innovation.

Andy Street, Mayor of the West Midlands, commented:

"We know just how important the healthcare and life sciences sector is to the
future prosperity of the West Midlands' economy, which is why we've made it
one of the key clusters to focus on as part of our Plan for Growth. I was
delighted therefore to have the opportunity to visit Celadon, which really is
at the cutting edge of cannabis-based medicines and has a key role to play in
our future plans.

"The UK may already have an established golden pharmaceutical triangle of
London, Oxford, and Cambridge - but Celadon's investment and expansion plans
show just how rapidly the West Midlands is becoming a key player in this
sector. I look forward to continuing to work with them and growing in
partnership."

James Short, Chief Executive Officer of Celadon, commented:

"We are proud members of the West Midlands' burgeoning life science community,
supported by leading institutions, such as Queen Elizabeth Hospital Birmingham
and Birmingham Medical School, and underpinned by the wide-ranging Deeper
Devolution Deal.

 

"Being located in the West Midlands means that we are never more than a few
hours away from ninety per cent of the UK, making it an ideal location. We are
hugely excited to be part of this regional growth story and remain immensely
grateful to Andy and the West Midlands Growth Company team for being such
supportive partners for our - and the West Midlands' - journey to life-science
leadership."

 

Figure 1: Andy Street with James Short, CEO of Celadon

 

Figure 2:  Andy Street (right), with James Short, CEO (left) and Arthur
Wakeley, MD (centre)

 

Figure 3:  Andy Street (far left), with Arthur Wakeley, MD (centre left), Dr
Tariq Ali, Deputy Pro-Vice Chancellor at the University of Birmingham (centre
right) and James Short, CEO (right)

 

Enquiries:

 Celadon Pharmaceuticals Plc
 James Short                                    Via Powerscourt

 Arthur Wakeley

 Jonathan Turner

 Powerscourt Group
 Sarah MacLeod / Nick Johnson / Sam Austrums /  +44 (0)20 7250 1446

 Ibrahim Khalil

About Celadon Pharmaceuticals Plc

Celadon Pharmaceuticals Plc is a UK based pharmaceutical company focused on
the research, cultivation, manufacturing, and sale of breakthrough
cannabis-based medicines. Its primary focus is on improving quality of life
for chronic pain sufferers, as well as exploring the potential of
cannabis-based medicines for other conditions such as autism. Its 100,000 sq.
ft UK facility is EU-GMP approved and comprises indoor hydroponic cultivation,
proprietary GMP extraction and manufacturing and an analytical and R&D
laboratory. Celadon's Home Office licence allows for the commercial supply of
its GMP pharmaceutical cannabis product. The Company's subsidiary, LVL, owns a
MHRA conditionally-approved clinical trial using cannabis based medicinal
products to treat chronic pain in the UK. Celadon also has a minority interest
in early-stage biopharma Kingdom Therapeutics which is developing a licenced
cannabinoid medicine to treat children with Autism Spectrum Disorder.

For further information please visit our website www.celadonpharma.co.uk
(http://www.celadonpharma.co.uk)

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAFIFSEERIEFIV